[Use of CSF biomarkers in the diagnostics of memory diseases].
Alzheimer's disease is the most common cause of dementia. Early diagnosis of diseases leading to dementia is cost-effective. However, early diagnosis of Alzheimer's disease may be difficult and should not be based on exclusion of other reasons for dementia. A decreased CSF amyloid beta-peptide-42 level together with elevated tau or phosphorylated tau levels can differentiate patients with AD from control subjects or patients with other neurologic conditions with relatively high accuracy. We evaluated the use of these biomarkers in 452 patient cohort during 2005-2007 in clinical practice. Cerebrospinal fluid biomarkers seem to be useful especially to confirm Alzheimer's disease diagnosis.
Remes
Anne
A
Oulun yliopisto, neurologian klinikka.
Leikola
Mika
M
Majamaa
Kari
K
Nikkanen
Matti
M
Ruokonen
Lotta-Iiris
LI
Rusanen
Minna
M
Tapiola
Tero
T
Ylikotila
Pauli
P
Vallittu
Anna-Maija
AM
Pirttilä
Tuula
T
D000544:Alzheimer Disease / Q000175:diagnosis*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D006801:Humans; D016875:tau Proteins / Q000134:cerebrospinal fluid*
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D016875:tau Proteins